Sakar Healthcare Limited (SAKAR) Fair Value & Analysis
Healthcare · IN · Market cap ₹18.9B
Fair value as of: Jul 3, 2026
From 24 valuation models · updated today
Share price +4.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹317.10 – ₹848.80 · fair‑value band ₹175.39 – ₹381.93 · the ₹848.80 price screens above the ₹305.54 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sakar Healthcare Limited (SAKAR) currently trades at ₹848.80, while our model-based Fair Value estimate is ₹305.54 — implying the stock looks roughly 64.0% overvalued today. We read business quality at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Sakar Healthcare Limited generated revenue of ₹2.5B at a net margin of 12.1%. Revenue grew 40.1% year over year. It earns a return on equity of 10.0%. Net debt stands at ₹550M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaesthetic, bronchodilator, adrenergic, sedative, anti-inflammatory, antiemetic, anticonvulsant, antipsychotic, antidepressant, and anti-cancer. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sakar Healthcare Limited reported revenue of ₹2.5B in FY2026 versus ₹1.3B in FY2022, a compound +18.4%/yr. Reported net income was ₹305M in FY2026, compounding +18.9%/yr from FY2022.
Is SAKAR fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sakar Healthcare Limited (SAKAR) undervalued?
What is the fair value of SAKAR?
What is the quality score of SAKAR?
What is the revenue of Sakar Healthcare Limited (SAKAR)?
What is the net profit margin of SAKAR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.